Orexigen Therapeutics (OREX) +4.7% premarket as the drug developer says it will close enrollment...


Orexigen Therapeutics (OREX) +4.7% premarket as the drug developer says it will close enrollment of new patients into its study of cardiovascular risks associated with its weight-loss treatment Contrave in Q4, sooner than expected. The move could cut in half the time needed before performing an interim analysis of the data.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs